Research links weight loss medications like Ozempic and Zepbound to certain serious eye conditions.

A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic and Wegovy, falsely claim they are FDA-approved.

Weight-loss drugs such as semaglutides or tirzepatides may raise patients’ risk of nonarteritic anterior ischemic optic ...

A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — ...

Impact on brown adipose tissue: Berberine may lower weight by increasing brown adipose tissue, a type of fat tissue that ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

semaglutide, tirzepatide, and liraglutide. Of these three drugs, only one - semaglutide - is currently approved and offered in an oral format. It is sold by Novo Nordisk under the brand name ...

Moran Eye Center at the University of Utah have published an investigatory review of nine patients who experienced vision complications while taking popular semaglutide and tirzepatide drugs ...

Two examples of GLP-1 medications currently on the market include semaglutide and tirzepatide. Semaglutide, also known by the brand name Ozempic, first saw widespread use after trial data showed ...

In May 2024, Novo Nordisk released the full results from its clinical trial, which showed a 24% risk reduction in kidney- and cardiovascular-related mortality from the once-weekly semaglutide 1.0 ...

Zepbound is a GLP-1 agonist containing tirzepatide, the same active ingredient found in ... Rybelsus is a GLP-1 agonist with semaglutide, like Ozempic and Wegovy, but it is taken as an oral pill ...